ME/CFS and Post-Viral Fatigue Syndrome have been among the most neglected diseases in modern medicine: underfunded, misunderstood, and without an objective diagnosis for decades. That is changing. A blood test with 96% accuracy is close to clinical approval. Clinical trials with promising compounds are running worldwide.
Patients are becoming an active part of the research community. Knowledge that was once reserved for specific circles is accessible to everyone today. Collect content from this site and feed it to the AI of your choice. As individual as this disease is, so should your approach to research be.
Every Sunday an automated system searches new scientific publications and evaluates them with AI for their relevance to ME/CFS and PVFS, including papers from other disciplines whose mechanisms may be transferable.Learn how it works →
Latest
Relevant research findings evaluated by Claude Opus and updated weekly.
Persistent killer T cells targeting SARS-CoV-2 and herpesviruses in Long COVID
In Long COVID, cytotoxic CD8+ T cells targeting SARS-CoV-2, EBV and CMV remain persistently active and exhausted, especially in women.
Read more ↓
The study shows that Long COVID patients retain terminally differentiated, exhausted, and highly cytolytic CD8+ T cells targeting SARS-CoV-2 as well as the herpesviruses EBV and CMV. Granzyme B-expressing killer cells are particularly prominent in women. The authors propose that failure to shut down this aggressive cytolytic response may drive Long COVID pathogenesis.
The findings link two central ME/CFS hypotheses: viral persistence (SARS-CoV-2) and latent herpesvirus reactivation (EBV, CMV). They provide potential biomarkers (cytolytic CD8+ T cells, granzyme B) and may help explain the higher disease prevalence in women.
COVID-19 and HIV: Similar Effects on the Immune System?
The article compares the immunological consequences of COVID-19 and HIV, showing similarities such as immune cell exhaustion, accelerated aging, and neurocognitive disorders.
Read more ↓
The authors analyze how SARS-CoV-2 – similar to HIV – leads to immune cell depletion, dysfunction, and exhaustion, increasing susceptibility to opportunistic infections. They discuss shared mechanisms such as accelerated aging and neurocognitive disorders and highlight societal responses to both pandemics.
Immune cell exhaustion and chronic immune dysfunction after SARS-CoV-2 are central hypotheses to explain Long COVID and ME/CFS. Comparison with HIV may provide new approaches for understanding and treatment.
Integrated Care Pathways for Long COVID: The STIMULATE-ICP Trial
A large trial shows multidisciplinary care reduces fatigue in Long COVID, while additional multi-organ MRI or digital rehabilitation showed no clear added benefit.
Read more ↓
In this phase 3 cluster-randomized trial with 1,152 Long COVID patients, fatigue scores (FAS) improved by 4.5 points across all arms at 12 weeks. Neither multi-organ MRI (Coverscan) nor digital rehabilitation ('Living with COVID Recovery') showed significant advantages over standard multidisciplinary care. Authors conclude that holistic clinical care is associated with fatigue reduction.
Long COVID substantially overlaps with ME/CFS. The trial provides data on care models and suggests digital rehabilitation may help long-term. Important caveat: For ME/CFS, activity-based approaches carry PEM risks, and this aspect remains unclear in the study.
Monocyte alterations and inflammation-coagulation crosstalk in Long COVID
Long COVID patients show reduced monocytes and platelets along with signs of impaired fibrinolysis and chronic vascular inflammation.
Read more ↓
The study combined clinical blood parameters from 45 individuals with transcriptomic analysis and found significantly reduced white blood cells, monocytes and platelets, as well as prolonged clotting time (APTT) in Long COVID patients. Key genes such as SERPINE1, PLAUR and CD44 were upregulated, suggesting monocyte adhesion to the endothelium and impaired clot dissolution (hypofibrinolysis). The findings support an immunothrombosis model as a possible disease mechanism.
The study supports the hypothesis of microthrombi and endothelial dysfunction in Long COVID and identifies specific target genes for future diagnostics and therapies — a central mechanism also discussed for ME/CFS.
Hyperbaric oxygen therapy alleviates cognitive impairment in CFS mouse model
Hyperbaric oxygen therapy improved cognitive function in a CFS mouse model by reducing neuroinflammation via the PLA2G4A-glycerophospholipid metabolic pathway.
Read more ↓
In a CFS mouse model, hyperbaric oxygen therapy (HBO) improved fatigue-like behavior and spatial/recognition memory. HBO reduced hippocampal neuronal injury, preserved blood-brain barrier integrity, and decreased pro-inflammatory cytokines and microglial activation. The effect was linked to suppression of PLA2G4A signaling and reduced levels of the inflammatory lipid mediator PGE2.
Cognitive impairment (brain fog) and neuroinflammation are core ME/CFS symptoms. This study identifies a specific molecular mechanism (PLA2G4A) and demonstrates that HBO – a clinically available therapy – can specifically intervene, with direct therapeutic implications.
Immunothrombosis in COVID-19 and its link to Long COVID
Long COVID patients still show a molecular signature of endothelial activation, platelet reactivity, and low-grade vascular inflammation three months after acute illness.
Read more ↓
A longitudinal multi-omics study of hospitalized COVID-19 patients found immunothrombosis-related pathways dominated the acute phase. Patients who developed Long COVID retained a distinct transcriptional signature at three months with platelet reactivity, complement dysregulation, and low-grade vascular inflammation, distinguishing them from fully recovered individuals.
The study provides measurable biomarkers for Long COVID and supports hypotheses on microthrombosis, endothelial dysfunction, and complement activation as persistent mechanisms – central themes also in ME/CFS.
IL-6 Family Cytokines in Acute COVID-19 and Long COVID: Mechanisms and Therapies
A review shows how the IL-6 cytokine family contributes to persistent inflammation in Long COVID and may serve as a target for new therapies.
Read more ↓
The review describes how IL-6 and related cytokines orchestrate both antiviral defense and maladaptive inflammation, potentially explaining the heterogeneity of COVID-19 outcomes and Long COVID symptoms. Novel therapeutic approaches such as multispecific fusion proteins could selectively modulate these signaling pathways. The authors emphasize that IL-6 family cytokines may also serve as biomarkers of disease progression.
Elevated IL-6 levels and chronic inflammation are central mechanisms in ME/CFS and Long COVID. Better understanding of the IL-6 family could lead to biomarkers and targeted therapies that may also help in post-viral fatigue syndrome.